Vancomycin minimum inhibitory concentrations and outcome in patients with severe staphylococcus aureus infection

Journal of Infectious Diseases

Volumn 205, Issue 5, 2012, Pages 864-865

  Gould, Ian Malcolm ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; FEMALE; GENES, BACTERIAL; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84856928478     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir848     Document Type: Letter

References (9)

1. Holland TL, Fowler VG. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet. J Infect Dis 2011; 204:329-31.
2. Rubinstein E, Lalani T, Corey R, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
3. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
4. Maor Y, Hagin M, Belauso N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199:1-6.
5. Sakoulas G, Moise PA, Rybak MJ. Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings? J Infect Dis 2009; 199:1558-9.
6. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997-8.
7. MwangiMM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-6. (Pubitemid 47185800)
8. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32:378-85.
9. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC "creep" method dependent? Analysis of methicillinresistant S. aureus (MRSA) susceptibility trends in blood isolates from North East Scotland, 2006-10. J Clin Microbiol 30 Nov 2011 [Epub ahead of print].